Literature DB >> 12769183

The changing pattern of HIV neuropathology in the HAART era.

Françoise Gray1, Fabrice Chrétien, Anne Valérie Vallat-Decouvelaere, Francesco Scaravilli.   

Abstract

Highly active antiretroviral treatment (HAART), which has been available for most AIDS patients in France since 1996, has resulted in a dramatic improvement of the progression of the disease. From the survey of our series of 343 brains with acquired immunodeficiency syndrome (AIDS) from patients who died between 1985 and 2002, we found both quantitative and qualitative changes in the pattern of human immunodeficiency virus (HIV) neuropathology. Quantitatively, despite a dramatic decrease in the number of autopsies, brain involvement remained a major cause of death. There was an overall decrease in incidence of cerebral toxoplasmosis, cytomegalovirus encephalitis (CMVE), and HIV encephalitis (HIVE), for which successful treatment is available. This contrasted with the unchanged incidence of progressive multifocal leukoencephalopathy (PML) and malignant non-Hodgkin lymphomas (MNHL). However, when looking closer at the 3 last years, the incidence of diseases affecting patients with severe immunodepression (CMVE, PML, and MNHL) decreased between 2000 and 2002, whereas infections occurring in patients with milder immunodeficiency, toxoplasmosis, varicella-zoster encephalitis (VZVE), or herpes simplex virus encephalitis (HSVE) became more frequent. In addition, we found uncommon types of brain infection such as BK virus encephalitis or general paresis. Finally, we described new variants of HIVE: severe leukoencephalopathy with intense perivascular macrophage and lymphocyte infiltration, possibly due to an exaggerated response from a newly reconstituted immune system, and chronic "burnt out" forms of HIVE as VZVE, toxoplasmosis, or PML, possibly associated with prolonged survival, in which neither inflammation nor organisms could be detected. These findings are compared with those reported in other neuropathological studies from different developed countries.

Entities:  

Mesh:

Year:  2003        PMID: 12769183     DOI: 10.1093/jnen/62.5.429

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  82 in total

1.  Neuropsychological evaluation and follow up in jcv- and non-jcv-related leukoencephalopathies in HIV infection.

Authors:  C Zucchella; E Sinforiani; E Tavazzi; S Del Bue; S Novati; R Maserati; M Ceroni; S Bastianello; L Minoli; P Ferrante; E Marchioni
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

Review 2.  Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Authors:  Takayuki Shiomi; Vincent Lemaître; Jeanine D'Armiento; Yasunori Okada
Journal:  Pathol Int       Date:  2010-07       Impact factor: 2.534

Review 3.  Progressive multifocal leukoencephalopathy and newer biological agents.

Authors:  Joseph R Berger
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

Review 4.  Cerebral infections.

Authors:  Spyros Karampekios; John Hesselink
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

5.  Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients.

Authors:  Dianne Langford; Jennifer Marquie-Beck; Sergio de Almeida; Deborah Lazzaretto; Scott Letendre; Igor Grant; J Allen McCutchan; Eliezer Masliah; Ronald J Ellis
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

Review 6.  Biomarkers for neuroAIDS: the widening scope of metabolomics.

Authors:  Gurudutt Pendyala; Elizabeth J Want; William Webb; Gary Siuzdak; Howard S Fox
Journal:  J Neuroimmune Pharmacol       Date:  2006-10-10       Impact factor: 4.147

7.  Monoclonal antibodies and progressive multifocal leukoencephalopathy.

Authors:  Joseph R Berger; Sidney A Houff; Eugene O Major
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

Review 8.  Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders.

Authors:  Jerel Adam Fields; Wilmar Dumaop; Leslie Crews; Anthony Adame; Brian Spencer; Jeff Metcalf; Johnny He; Edward Rockenstein; Eliezer Masliah
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

Review 9.  Demyelinating diseases.

Authors:  S Love
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

10.  Unmasking of PML by HAART: unusual clinical features and the role of IRIS.

Authors:  Navdeesh Sidhu; J Allen McCutchan
Journal:  J Neuroimmunol       Date:  2009-12-04       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.